EMA Authorised: Uzpruvo (ustekinumab) — Stada Arzneimittel AG

View source ↗

Summary

EMA authorised Uzpruvo (ustekinumab) for the treatment of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Ulcerative Colitis

Drugs mentioned

• Uzpruvo (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Crohn Disease;Colitis, Ulcerative. MAH: Stada Arzneimittel AG. Decision date: 30/01/2026